Macro and microeconomics of blue light cystoscopy with CYSVIEW® in non-muscle invasive bladder cancer.

To determine the estimated budget impact to practices that incorporate blue light cystoscopy (BLC) with hexaminolevulinate HCl (HAL) for the surveillance of non-muscle-invasive bladder cancer (NMIBC) in the clinic setting.

With the introduction of advanced technologies in the clinic setting such as HAL, further cost comparative research is needed to justify HAL as a high value option.

A budget impact model was developed from the facility perspective assessing projected costs at 2 years for a simulated facility with 50 newly diagnosed bladder cancer patients. Treatment and surveillance cystoscopy intervals were based on clinical guidelines. Clinical inputs, including tumor stage and grade at diagnosis, rates of recurrence and relative risk reduction when using BLC with HAL, were derived from published studies. Cost inputs were based on Medicare reimbursement rates and facility costs.

Use of BLC identified 9 additional recurrences over two years compared to white light cystoscopy alone. Use of flexible BLC for surveillance marginally increased costs to the practice, with a net difference of $0.76 per cystoscopy over 2 years.

From the office/clinic perspective, the model suggests that the use of flexible BLC for the surveillance of NMIBC may not impact cost per cystoscopy and identifies 9 recurrences over 2 years that would be missed using white light cystoscopy alone. These findings could have important implications in the management of NIMBC and help guide clinical practice guidelines that promote cost-effective care and improved patient outcomes.

Urologic oncology. 2021 Jun 20 [Epub ahead of print]

Stephen B Williams, Meghan B Gavaghan, Anthony Fernandez, Siamak Daneshmand, Ashish M Kamat

Department of Surgery, Division of Urology, The University of Texas Medical Branch, Division of Urology, Galveston, TX. Electronic address: ., Ipsos Healthcare, New York, NY., Medical Affairs, Photocure Inc., Princeton, NJ., Department of Urology, University of Southern California, Urology and GU Oncology Los Angeles, Los Angeles, CA., Department of Urology, MD Anderson Cancer Center, Houston, TX.

Go Beyond the Abstract and Read a Commentary by the Author